
Explore Noninvasive Rejection Monitoring in Single Lung Transplantation; A SLAM Study Overview Presented by Natera
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
Acerca de esta escucha
In this episode of the ISHLT Voices podcast, hosted by Natera, you’ll hear a discussion on the need for noninvasive surveillance options for single lung transplantation and the role that the Prospera Lung donor derived cell free DNA (dd-cfDNA) test can play.
There are inherent, increased risks and challenges associated with management of single lung transplantation over double lung. Monitoring through invasive transbronchial biopsy procedures (TBBx) is often not the best option for these high-risk, frail patients.
In this podcast, notable transplant pulmonologists Drs. Rosenheck and Arunachalam highlight the need in the single lung population for noninvasive surveillance options. The Prospera Lung donor derived cell free DNA (dd-cfDNA) test has been validated in single and double lung transplants with emerging data in support of clinical utility. The expert speakers also discuss the recently published data in support of dd-cfDNA usage in the single lung transplant population from the SLAM study.
Justin Rosenheck, DO
Assistant Professor of Internal Medicine
Ohio State University | Columbus, OH USA
Ambalavanan Arunachalam, MD
Assistant Professor, Medicine (Pulmonary and Critical Care)
Northwestern Medicine | Chicago, IL USA
The content of this podcast was developed entirely by ISHLT's industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.